Belite Bio, Inc (NASDAQ:BLTE – Free Report) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Belite Bio in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim forecasts that the company will post earnings of ($1.29) per share for the year. The consensus estimate for Belite Bio’s current full-year earnings is ($1.21) per share.
Belite Bio (NASDAQ:BLTE – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.02. During the same period in the previous year, the company posted ($0.40) earnings per share.
Check Out Our Latest Stock Analysis on BLTE
Belite Bio Price Performance
BLTE stock opened at $58.22 on Wednesday. Belite Bio has a 1 year low of $31.00 and a 1 year high of $86.53. The firm has a market capitalization of $1.80 billion, a PE ratio of -52.45 and a beta of -1.56. The business has a 50 day simple moving average of $65.38 and a 200-day simple moving average of $57.61.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new position in Belite Bio during the 2nd quarter worth approximately $6,761,000. State Street Corp raised its position in Belite Bio by 28.2% in the third quarter. State Street Corp now owns 20,086 shares of the company’s stock worth $942,000 after acquiring an additional 4,415 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Belite Bio by 48.1% in the fourth quarter. GAMMA Investing LLC now owns 1,290 shares of the company’s stock valued at $81,000 after acquiring an additional 419 shares during the period. XTX Topco Ltd purchased a new position in shares of Belite Bio in the 3rd quarter valued at about $253,000. Finally, JPMorgan Chase & Co. boosted its holdings in Belite Bio by 7,122.7% during the third quarter. JPMorgan Chase & Co. now owns 6,356 shares of the company’s stock worth $298,000 after buying an additional 6,268 shares in the last quarter. 0.53% of the stock is currently owned by hedge funds and other institutional investors.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
Recommended Stories
- Five stocks we like better than Belite Bio
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- After a Reset Year, Is Moderna Stock Poised for a Comeback?
- Best Aerospace Stocks Investing
- Retail Trends Spark Analyst Upgrades for DICK’s Sporting Goods
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Teck Resources: America’s Ally in Rare Earth Elements
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.